Abstract
The aim of the present study was to prepare a resveratrol-loaded microsponge-based dry powder inhaler (RES-MS-DPI) using the quasi-emulsion solvent diffusion method and to explore its suitability for pulmonary delivery. The prepared microsponges were evaluated for physicochemical properties. Additionally, an in vitro lung deposition study was performed using an Andersen cascade impactor (ACI), while in vivo performance was studied by intratracheal administration. The optimized porous and spherical RES-MS showed particle size, surface charge, entrapment efficiency, mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) of 2.499 ± 0.56 μm, −25.34 mV, 89.45 ± 0.23%, 2.13 ± 0.21 μm and 48.54 ± 0.25%, respectively, with controlled release. Further, in vitro and in vivo studies of RES-MS showed a twofold improvement in the FPF, and 4.4-, 14.12- and 1.94-fold improvement in the area under the curve (AUC), mean residence time (MRT) and Cmax. The RES-MS exhibited higher aerosolization and lung deposition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
